Premier Alternatives

PreciseDx

New York, NY · Founded 2020 · Privately Held (backing)

Developer of artificial intelligence-guided pathology diagnostics designed to improve patient outcomes in the field of cancer and other diseases. PreciseDx is based in New York, NY and was founded in 2020. It was valued at $41.5 million at its later-stage round in Jun 2025, the last priced event on record. It has raised $42.8 million across 2 recorded rounds; the latest was an $11.2 million early-stage round in May 2025.

PMV mark · valuation
$41.5M
Oct 2026
Priced at
its later-stage round
Jun 2025
Total raised
$42.8M
Last round
Early Stage VC
May 2025

PreciseDx key facts

as of Oct 2026
  • Developer of artificial intelligence-guided pathology diagnostics designed to improve patient outcomes in the field of cancer and other diseases.
  • PreciseDx is valued at approximately $41.5M as of Oct 2026, set at its later-stage round, Jun 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $42.8M across 2 recorded rounds; the latest was Early Stage VC ($11.2M) in May 2025.
  • Notable investors include Labcorp Venture Fund, MSD Global Health Innovation Fund, GenHenn Capital, Agilent Technologies, Eventide Asset Management — 11 tracked in total.
  • PreciseDx has filed 2 Form Ds with the SEC since 2024, most recently Jun 2025 ($11.2M sold to 9 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$41.5M

Valued at $41.5M at its later-stage round, Jun 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of PreciseDx with a free account
  • ·The complete investor list: 11 names
  • ·Watch PreciseDx: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

PreciseDx funding rounds

2 rounds
May 2025Early Stage VC$11.2MSEC filing▮
Feb 2024Early Stage VC$20.7MSEC filing▮
Full funding history →

PreciseDx valuation

PreciseDx was valued at $41.5 million at its later-stage round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has PreciseDx raised?

PreciseDx has raised $42.8 million in total; 2 of its rounds are on record. The largest on record was a $20.7 million early-stage round in Feb 2024; the most recent was an $11.2 million early-stage round in May 2025.

PreciseDx has filed 2 Form Ds with the SEC since 2024, most recently in Jun 2025 ($11.2 million sold to 9 investors).

PreciseDx investors

11 investors are on record for PreciseDx, including Labcorp Venture Fund, MSD Global Health Innovation Fund, GenHenn Capital and Agilent Technologies. The early-stage round in May 2025 drew 9 investors.

About PreciseDx

Developer of artificial intelligence-guided pathology diagnostics designed to improve patient outcomes in the field of cancer and other diseases. The company's commercial, regulatory, and translational research experience enables the advancement of technologies across diverse areas such as clinical modeling, patient phenotyping, image analysis, and the practical use of big data in a real-world setting, enabling patients to improve their quality of life.

Sector
Healthcare
HQ
New York, NY, United States
Founded
2020
Employees
29
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.